The Pharma Letter Podcast — Episode 25 — The need for change for major depressive disorder patients

References:

1. Lim G et al. Sci Rep. 2018;8:2861.
2. Reif A et al. N Engl J Med. 2023;389:1298-309.
3. Ionescu DF et al. Dialogues Clin Neurosci. 2015;17(2):111–126.
4. Chronic illness and mental health. National Institute of Mental Health 2021. Available at: https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health [Accessed November 2023].
5. Mental disorders. World Health Organization 2022. Available at: https://www.who.int/news-room/fact-sheets/detail/mental-disorders [Accessed November 2023].
6. Becker AE et al. N Engl J Med. 2013;369:66-73.
7. Schneider F et al. Ger Med Sci. 2004;2:Doc)1.
8. World Health Organization (WHO) Depressive Disorder. Available at: https://www.who.int/news-room/fact-sheets/detail/depression [Accessed November 2023]
9. Guideline on clinical investigation of medicinal products in the treatment of depression. European Medicines Agency 2013. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf [Accessed November 2023].
10. Wang, G et al. Neuropsychiatr Dis Treat. 2020;16(16):221-234
11. Mrazek DA et al. Psychiatr Serv. 2014;65(8):977-987.
12. Amos T et al. J Clin Psychiatr. 2018;79(2):17m11725.
13. Souery D et al. J Clin Psychiatry. 2007;68:1062–70.
14. Lopez Munoz et al. Curr Pharm Des. 2009; 15 (14):1563-86.
15. A long-term comparison of esketamine nasal spray versus quetiapine extended release, both in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor, in participants with treatment resistant major depressive disorder (ESCAPE-TRD). NCT 04338321. Clinicaltrials.gov 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04338321?term=escape-trd&draw=2&rank=1 [Accessed November 2023].
16. Seroquel XR. European Medicines Agency 2010. Available at https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-xr [Accessed November 2023].
17. Heerlein, K et al. Most Common Treatments in Patients with Treatment Resistant Depression Based on European Cohort Study Real-World Evidence. Presented at ISPOR 2022, November 6-9. Poster HSD28.